On Demand webinar: 40% of men with type 2 diabetes have symptomatic testosterone deficiency – why are we still not finding and treating these men?

In the fourth of our 2022 ABCD webinar series, please join Dr Bob Ryder and Professor Hugh Jones to discuss symptomatic testosterone deficiency.

40% of men with type 2 diabetes have symptomatic testosterone deficiency.  Testosterone deficiency is associated with an adverse effect on cardiovascular risk factors, osteoporosis and psychological wellbeing amongst other issues. Testosterone deficiency is also associated with an increased mortality in type 2 diabetes.  Testosterone replacement has been shown to improve insulin resistance, lower HbA1c, lower cholesterol, reduce body weight, reduce mortality and make the patient feel better. 

In this webinar we will provide the scientific data behind the information just given and also explain with examples the benefits of the ABCD nationwide audit programme with explanation and encouragement as to why clinicians should change their practice to try and identify their patients with symptomatic testosterone deficiency and enter them into the ABCD worldwide audit of testosterone deficiency in men with type 2 diabetes.

Q& A will follow this presentation



Professor Hugh Jones
Hugh is Honorary Professor of Andrology in the Department of Human Metabolism the University of Sheffield Medical School, Sheffield, UK and Hon. Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield. He is  a clinical and laboratory researcher into the role of testosterone in the pathogenesis and treatment of type 2 diabetes and cardiovascular disease. He has also conducted research on the hypothalamic and paracrine control of anterior pituitary hormone secretion, among others. 'Professor Jones is President of the Androgen Society (International). He is also on the European Association of Urology guideline committee for Sexual and Reproductive Health and also the British Society for Sexual Medicine guideline committee for the Management of Testosterone Deficiency. He was also on the International Consultation on Men' Health and Infertility. He was the first to demonstrate the following (1) the high prevalence of symptomatic testosterone deficiency in men with type 2 diabetes, (2) testosterone replacement improves insulin resistance, (3) reduces mortality in hypogonadal men with type 2 diabetes and (4) recently shown testosterone replacement has benefits on quality of life in these men.



Dr Bob Ryder
Bob Ryder trained in South Wales and Sheffield.  He has worked as a Consultant Physician/Diabetologist/Endocrinologist, City Hospital, Birmingham since 1991. Over the years special interests have included diabetic retinopathy screening; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone He leads the ABCD nationwide audits of new therapies and devices – current/imminent audits include SGLT2i, liraglutide, exenatide qw, IDegLira, degludec, FreeStyle Libre, semaglutide, testosterone, closed-loop systems.  He is chief investigator of two ABCD Endobarrier studies (https://youtu.be/xRcnMBOdb58, https://youtu.be/y1zm0Scq6YM). Beyond diabetes he is best known as principal author of best-selling "An Aid to the MRCP Short Cases", the 4th-edition of which is the three volume “An Aid to the MRCP PACES”.




Dr Dinesh Nagi
Dr Dinesh Nagi is currently working as an Honorary Consultant in Diabetes and endocrinology at Pinderfields Hospital Wakefield. Having served as Chairman of  the ABCD between 2017-2020,  he has recently  taken up the role of Vice-Chairman of the DCT (Diabetes Care Trust) UK, a charitable trust which works closely  with the ABCD. His main interest in diabetes was to promote Integrated Diabetes Care among Primary and Specialist Diabetes Services. 

Clinical taxonomy: 
Inpatient care
Treatments for diabetes
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Resource taxonomy: 
ABCD Webinar Series
Event resources

Thank you to our Gold Supporters

Corporate Pharma supporters: Astra Zeneca, Lilly and Sanofi. Pump and device supporters: Abbott Laboratories Ltd, Dexcom, GlucoRx, Insulet International Ltd, Ypsomed Ltd

This webinar has been instigated and organised by ABCD. The support from our corporate sponsors has allowed us to provide this valuable educational meeting free of charge to all delegates. Sponsors have had no input into the agenda or the selection of speakers.


  • The views expressed by speakers or other thirds parties are those of the speaker or third party and not necessarily of ABCD.
  • Whilst every effort has been made to ensure the information and guidance is accurate, it is impossible to predict all the circumstances in which it may be used and ABCD assumes no responsibility or liability for any errors or omissions made in this content. All presentations are for informational and educational purposes only - content should not be considered applicable to all situations or patients.
  • The contents do not negate the requirement for comprehensive assessment, liaison and management of patients, their families and caregivers.
  • ABCD neither endorses nor accepts responsibility for the contents of third party websites or resources included in these presentation. 
  • Sponsors have had no input into the content of the presentations.
  • For more information see our Website Terms and Conditions.

ABCD Webinar Series

ABCD Webinars